Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
📊 Key Statistics
Market Cap$2M
P/E Ratio—
EPS (TTM)—
EPS YoY—
Revenue YoY—
Float—
Short Float %—
Inst. Ownership—
Sector RS—
📈 Fundamentals
ROE—
ROIC—
ROA—
Current Ratio—
Debt/Equity—
Gross Margin—
Net Margin—
Dividend Yield—
Next Earnings—
⚡ Options Summary
Call OI—
Put OI—
P/C Ratio (OI)—
Gamma Environment—
Max Pain—
Call Wall—
Put Wall—
🎯 Analyst Estimates
Consensus Target—
High Target—
Low Target—
Analysts—
Upside/Downside—
📋 Quarterly Financials
| Period |
Revenue |
Rev YoY |
EPS |
EPS YoY |
Gross Margin |
🔥 Recent Options Flow
| Type | Strike | Exp | Size | Premium | Time |
|---|
🏛️ Institutional Trades
| Type | Price | Size | Value | Venue | Time |
|---|
🏦 Top Institutional Holders
| Institution | Shares | Value | % of Class |
|---|